Clinical and molecular characterization of HER2 amplified-pancreatic cancer

Genome Medicine

Volumn 5, Issue 8, 2013, Pages

  Chou, Angela ^a,b,c   Waddell, Nicola ^f   Cowley, Mark J ^a,c   Gill, Anthony J ^a,d,e   Chang, David K ^a,k,l   Patch, Ann Marie ^f   Nones, Katia ^f   Wu, Jianmin ^a,c   Pinese, Mark ^a,c   Johns, Amber L ^a   Miller, David K ^f   Kassahn, Karin S ^f   Nagrial, Adnan M ^a,c   Wasan, Harpreet ^g   Goldstein, David ^h   Toon, Christopher W ^d,e,i   Chin, Venessa ^a,c   Chantrill, Lorraine ^a,c,j   Humphris, Jeremy ^a   Mead, R S ^a,b,c   Rooman, Ilse ^a,c   Samra, Jaswinder S ^d   Pajic, Marina ^a,c   Musgrove, Elizabeth A ^a,k   Pearson, John V ^f   Morey, Adrienne L ^b   Grimmond, Sean M ^f,k   Biankin, Andrew V ^a,k,l   more..

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d ROYAL NORTH SHORE HOSPITAL   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ Histopath Pathology   (Australia)

^j Liverpool and Macarthur Cancer Therapy Centres   (Australia)

^k UNIVERSITY OF GLASGOW   (United Kingdom)

^l GLASGOW ROYAL INFIRMARY   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER INCIDENCE; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE LOCUS; GENE SEQUENCE; HUMAN; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; STOMACH CANCER;

EID: 84883193815     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm482     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Showalter SL, Charles S, Belin J, Cozzitorto J, Einstein P, Richards NG, Sauter PK, Kennedy EP, Witkiewicz A, Brody JR, Yeo CJ. Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. Expert Opin Drug Deliv 2010, 7:273-284. 10.1517/17425240903544462, 20201734.
3. Biankin AV, Hudson TJ. Somatic variation and cancer: therapies lost in the mix. Hum Genet 2011, 130:79-91. 10.1007/s00439-011-1010-0, 21643984.
4. Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small cell lung cancer. Clin Cancer Res 2006, 12:4377s-4383s. 10.1158/1078-0432.CCR-06-0115, 16857814.
5. McAlpine JN, Wiegand KC, Vang R, Ronnett BM, Adamiak A, Kobel M, Kalloger SE, Swenerton KD, Huntsman DG, Gilks CB, Miler DM. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC cancer 2009, 9:433. 10.1186/1471-2407-9-433, 2803495, 20003286.
6. Hudson TJ, Anderson W, Aretz A, et al. International Network of Cancer Genome Projects. Nature 2010, 464:993-998. 10.1038/nature08987, 2902243, 20393554.
7. Hede K. Superhighway or blind alley? The cancer genome atlas releases first results. J Natl Cancer Inst 2008, 100:1566-1569. 10.1093/jnci/djn424, 3299220, 19001600.
8. Samuel N, Hudson TJ. The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nature Rev Gastroenterol Hepatol 2012, 9:77-87.
9. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491:399-405. 10.1038/nature11547, 3530898, 23103869.
10. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamlyama H, Jimeno A, Hong SMFB, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806. 10.1126/science.1164368, 2848990, 18772397.
11. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697. 10.1016/S0140-6736(10)61121-X, 20728210, ToGA Trial Investigators.
12. Law LY. Dramatic response to trastuzumab and Paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. J Clin Oncol 2012, 30:e271-e273. 10.1200/JCO.2012.42.3061, 22851567.
13. Buchler P, Reber HA, Buchler MC, Roth MA, Büchler MW, Friess H, Isacoff WH, Hines OJ. Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J Gastrointest Surg 2001, 5:139-146. 10.1016/S1091-255X(01)80025-1, 11331475.
14. Kimura K, Sawada T, Komatsu M, Inoue M, Muguruma K, Nishihara T, Yamashita Y, Yamada N, Ohira M, Hirakawa K. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 2006, 12:4925-4932. 10.1158/1078-0432.CCR-06-0544, 16914581.
15. Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, Tantravahi U, Hughes TM, Maia C, Pasquariello T, Goldstein L, King T, Tsai JY, Kennedy T. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 2004, 22:706-712. 10.1081/CNV-200032974, 15581051.
16. Harder J, Ihorst G, Heinemann V, Hofheinz R, Moehler M, Buechler P, Kloeppel G, Röcken C, Bitzer M, Boeck S, Endlicher E, Reinacher-Schick A, Schmoor C, Geissler M. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 2012, 106:1033-1038. 10.1038/bjc.2012.18, 3304403, 22374460.
17. Australian Pancreatic Cancer Genome Initiative. http://www.pancreaticcancer.net.au.
18. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167. 10.1200/JCO.2008.18.1370, 2667820, 19204204.
19. Chang DK, Johns AL, Merrett ND, Gill AJ, Colvin EK, Scarlett CJ, Nguyen NQ, Leong RW, Cosman PH, Kelly MI, Sutherland RL, Henshall SM, Kench JG, Biankin AV. Margin clearance and outcome in resected pancreatic cancer. J Clin Oncol 2009, 27:2855-2862. 10.1200/JCO.2008.20.5104, 19398572.
20. Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA, Samra JS, Gill AJ, Kench JG, Merrett ND, Das A, Musgrove EA, Sutherland RL, Biankin AV. NSW Pancreatic Cancer Network The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Annal Oncol 2012, 23:1713-1722. NSW Pancreatic Cancer Network.
21. Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008, 52:797-805. 10.1111/j.1365-2559.2008.03028.x, 18422971.
22. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, Nielsen TO, Gelmon K. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010, 28:3271-3277. 10.1200/JCO.2009.25.9820, 20498394.
23. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC, Debois M, van Cutsem E, van Dekken H, Klinkenbijl JH, Jeekel J. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007, 246:734-740. 10.1097/SLA.0b013e318156eef3, 17968163.
24. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P, Herman JM, Cameron JL, Yeo CJ, Halushka MK, Eshleman JR, Raben M, Klein AP, Hruban RH, Hidalgo M, Laheru D. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009, 27:1806-1813. 10.1200/JCO.2008.17.7188, 2668706, 19273710.
25. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 2011, 1:44-53. 10.1158/2159-8274.CD-10-0010, 22586319.
26. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Van't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012, 30:3242-3249. 10.1200/JCO.2011.39.2779, 3434983, 22649152.
27. Medical Research Council Clinical Trial, http://www.focus4trial.org.
28. Galsky MD, Von Hoff DD, Neubauer M, Anderson T, Fleming M, Nagarwala Y, Mahoney JM, Midwinter D, Vocila L, Zaks TZ. Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs 2012, 30:695-701. 10.1007/s10637-010-9541-0, 20857170.